| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
PD 123319 [PD-123319; PD123319; (S)-(+)-PD 123319] is a novel, potent, and selective AT2 (angiotensin II) receptor antagonist with anti-hypertensive effects. It inhibits AT2 with an IC50 of 34 nM. It displaces 125I-labeled angiotensin II from a specific subset of angiotensin II binding sites in rat adrenal preparations. PD 123319 has been used to selectively examine the specific roles for AT1R and AT2R in hypertensive and other vascular research-related models. PD-123319 is found to prevent Ang II from binding the bovine zona glomerulosa microsomal preparation with IC50 value of 6.9nM in the binding assay using microsome.
| ln Vitro |
It has been demonstrated that in a variety of tissues, PD 123319 can distinguish between two subclasses of AII receptors. Two kinds of binding sites for AII in a membrane preparation of bovine adrenal glomerulosa cells are selectively labeled by 125I-AII. With a strong affinity (IC50 of 92.9 nM) for DuP-753, the first class (DuP-753 sensitive) accounts for around 85% of all AII binding sites. Regarding 125I-AII binding to this location, PD-123319 has no effect. With an IC50 of 6.9 nM for PD-123319 and an IC50 of approximately 10 microM for DuP-753, the second class of binding sites exhibits greater sensitivity[2].
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
[1]. Blankley CJ, et al. Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J Med Chem. 1991 Nov;34(11):3248-60.
[2]. Boulay G, et al. Modulation of angiotensin II binding affinity by allosteric interaction of polyvinyl sulfate with an intracellular domain of the DuP-753-sensitive angiotensin II receptor of bovine adrenal glomerulosa. Mol Pharmacol. 1992 Apr;41(4):809-15 [3]. Estrup TM, et al. No effect of angiotensin II AT(2)-receptor antagonist PD 123319 on cerebral blood flow autoregulation. J Renin Angiotensin Aldosterone Syst. 2001 Sep;2(3):188-92. [4]. Brillante DG, et al. Effects of intravenous PD 123319 on haemodynamic and arterial stiffness indices in healthy volunteers. J Renin Angiotensin Aldosterone Syst. 2005 Sep;6(2):102-6 |
| Molecular Formula |
C31H32N4O3
|
|
|---|---|---|
| Molecular Weight |
508.61
|
|
| CAS # |
130663-39-7
|
|
| Related CAS # |
PD 123319 ditrifluoroacetate;136676-91-0
|
|
| SMILES |
O=C([C@@H]1CC2=C(N=CN2CC3=CC=C(N(C)C)C(C)=C3)CN1C(C(C4=CC=CC=C4)C5=CC=CC=C5)=O)O
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9661 mL | 9.8307 mL | 19.6614 mL | |
| 5 mM | 0.3932 mL | 1.9661 mL | 3.9323 mL | |
| 10 mM | 0.1966 mL | 0.9831 mL | 1.9661 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA